Balance Sheet
Cash Flow Statement
AmortizationBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Gains from Investment Securities (2024 - 2025)

Historic Gains from Investment Securities for Abivax (ABVX) over the last 2 years, with Q3 2025 value amounting to $35.0 million.

  • Abivax's Gains from Investment Securities changed N/A to $35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year change of. This contributed to the annual value of $32.0 million for FY2024, which is 265370.12% up from last year.
  • Abivax's Gains from Investment Securities amounted to $35.0 million in Q3 2025.
  • Abivax's 5-year Gains from Investment Securities high stood at $35.0 million for Q3 2025, and its period low was -$2.3 million during Q2 2025.